Q3 2023 Results

Company overview Financial review Conclusions Innovation: Pipeline overview Financial performance Cardiovascular Immunology Neuroscience RydaptⓇ - Multi-targeted kinase inhibitor NCT03591510 (CPKC412A2218) Indication Acute myeloid leukemia, pediatrics Phase 2 Phase Patients 20 Primary Outcome Measures Arms Intervention Target Patients Occurrence of dose limiting toxicities Safety and Tolerability Chemotherapy followed by Midostaurin Newly diagnosed pediatric patients with FLT3 mutated acute myeloid leukemia (AML) Readout 2026 Milestone(s) Publication TBD Appendix Innovation: Clinical trials Oncology References Abbreviations Other 73 Investor Relations | Q3 2023 Results NOVARTIS | Reimagining Medicine

View entire presentation